Who Owns CytomX Therapeutics Stock?
NASDAQ: CTMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 102.88%
- Institutions (% of float)
- 103.47%
- Held by insiders
- 0.57%
- Institutional holders
- 254
- Institutions 99.4%
- Insiders 0.6%
- Public and other 0.0%
Who owns CytomX Therapeutics stock?
Institutional investors own about 102.9% of CytomX Therapeutics's shares, spread across 254 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.57% of CTMX.
The largest institutional holders are FMR, LLC (15.75%), Kynam Capital Management, LP (9.70%) and Blackrock Inc. (8.47%). Together, the top 10 institutions control 61.3% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their CTMX positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CTMX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 34.34M | 15.75% | +5.0% |
| Kynam Capital Management, LP | 21.14M | 9.70% | -2.6% |
| Blackrock Inc. | 18.47M | 8.47% | +5.2% |
| Bank of America Corporation | 11.57M | 5.31% | -23.3% |
| Perceptive Advisors Llc | 9.27M | 4.25% | -11.2% |
| State Street Corporation | 9.03M | 4.14% | -23.2% |
| Vanguard Capital Management LLC | 8.73M | 4.01% | +2.4% |
| Point72 Asset Management, L.P. | 8.60M | 3.95% | +10.2% |
| Citadel Advisors Llc | 7.01M | 3.22% | +125.4% |
| Two Sigma Investments, LP | 5.38M | 2.47% | +30.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CTMX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 6.23M | 2.86% |
| Fidelity Select Portfolios-Select Health Care Portfolio | 6.00M | 2.75% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 5.08M | 2.33% |
| iShares Trust-iShares Russell 2000 ETF | 4.88M | 2.24% |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 4.75M | 2.18% |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 3.97M | 1.82% |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 3.00M | 1.38% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.79M | 1.28% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 2.49M | 1.14% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2.10M | 0.96% |
Frequently asked questions
Who is the largest shareholder of CytomX Therapeutics?
FMR, LLC is the largest institutional shareholder of CTMX, owning 15.75% of shares outstanding (34.34M shares) as of its latest 13F filing.
What percentage of CytomX Therapeutics is owned by institutions?
Institutions own about 102.9% of CTMX shares and 103.5% of the public float.
How much of CytomX Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.57% of CTMX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.